SOCS3 and allergic asthma: In a murine model of chronic allergic asthma, the intranasal administration of a commercially designed suppressor of cytokine signaling 3 (SOCS3) siRNA resulted in the attenuation of airway inflammation and remodeling by reducing eosinophilia, mucus secretion, and airway hyperresponsiveness [94].